- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Marina Biotech announced the appointment of Isaac Blech to its board of directors.
Marina Biotech (OTCQB:MRNA) announced the appointment of Isaac Blech to its board of directors.
As quoted in the press release:
Additionally Marina Biotech also has entered into a Note Purchase Agreement with a trust affiliated with Mr. Blech pursuant to which the Company will issue a secured convertible promissory note in the aggregate principal amount of $500,000. The Note will become due and payable on March 31, 2018.
“We are honored to have such an accomplished biotech entrepreneur and investor such as Isaac joining our Board,” Dr. Vuong Trieu, Executive Chairman of Marina Biotech, stated. “Isaac’s impressive track record in helping to create and grow leading companies will be instrumental at this critical point in our company history. His involvement will allow us to move forward with the commercialization of our FDA-approved product Prestalia, and other innovative drugs for the treatment of hypertension, of which more than half of the 75 million patients are still struggling to achieve blood pressure control.”
Click here to read the full press release.
Source: globenewswire.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.